Cognitive Behavioral Therapy Following Myocardial Infarction (MI-CBT)

May 23, 2022 updated by: Brjann Ljotsson, Karolinska Institutet
Myocardial infarction (MI) is one of the leading cause s of health loss globally, representing a large proportion of general disability. Anxiety and depression occur in 20-30 percent of patients following MI and have been identified as risk factors for recurrent adverse cardiac event. The purpose of our this study is to develop and evaluate a disease specific cognitive behavioral therapy (C BT) protocol to reduce cardia anxiety, depression, increase physical inactivity and quality of life (Q oL) in patients following MI.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The study will include 20 patients. The MI-specific CBT lasts for 8 weeks and is delivered face-to-face via a secure digital video solution (to minimize cancelled sessions because of the COVID-19 pandemic) or at the Karolinska Universitetssjukhuset cardiac research unit, by licensed psychologists with expertise in CBT for cardiac disease. During treatment, the psychologists will have direct access to a cardiologist assigned to the project and treatments are conducted in close interdisciplinary collaboration to ensure patient safety.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stockholm, Sweden
        • Karolinska University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

( - )MI ≥ 6 months before assessment (type 1 STEMI/NSTEMI) ( - )Age 18-69 years endorsed cardiac anxiety that leads to significant distress or interferes with daily life (Cardiac Anxiety Questionnaire (CAQ); score ≥20) ( - ) On optimal medical treatment ( - )Able to read and write in Swedish.

Exclusion Criteria:

( - ) heart failure with severe systolic dysfunction (ejection fraction ≤ 35%) ( - ) significant valvular disease ( - ) planned coronary artery bypass surgery or other invasive therapy ( - ) other severe medical illness ( - )any medical restriction to physical exercise ( - )severe psychiatric disorder, severe depression, or risk of suicide ( - )alcohol dependency.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: MI-CBT
The treatment will be based on the AF treatment developed by the research group and further be developed and adapted during the course the study, based on the clinical presentation of the MI patients and their response to the CBT interventions detailed below. The MI-specific CBT will consist of 8 weekly face-to face digital video sessions with home assignments that can be reviewed and reported in the research groups secure platform. CBT for MI primarily targets two processes of disability; cardiac anxiety, and depressive inactivity
Education, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiac anxiety questionnaire
Time Frame: 2 months from baseline
Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
2 months from baseline
Cardiac anxiety questionnaire
Time Frame: 8 months from baseline
Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
8 months from baseline
Cardiac anxiety questionnaire
Time Frame: baseline
Measure of cardiac anxiety, fear, avoidance and attention. The score ranges between 0 and 72, with a greater score indicating elevated cardiac anxiety.
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Generalized Anxiety Disorder 7-item
Time Frame: Baseline
General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
Baseline
Generalized Anxiety Disorder 7-item
Time Frame: 2 months from baseline
General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
2 months from baseline
Generalized Anxiety Disorder 7-item
Time Frame: 8 months from baseline
General anxiety, score ranging from 0-21, with a higher score indicating more anxiety and worry.
8 months from baseline
The Godin Leisure-time Exercise
Time Frame: Baseline
Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
Baseline
Tampas Scale for Kinesophobia-Heart version
Time Frame: Baseline
Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
Baseline
12-Item Short-Form Health Survey (SF-12)
Time Frame: Baseline
General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
Baseline
12-Item Short-Form Health Survey (SF-12)
Time Frame: 2 months from baseline
General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
2 months from baseline
12-Item Short-Form Health Survey (SF-12)
Time Frame: 8 months from baseline
General quality of life, with a score ranging from 0 to 100. A higher score indicating a better quality of life.
8 months from baseline
Body Sensation Questionnaire
Time Frame: Baseline
Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
Baseline
Body Sensation Questionnaire
Time Frame: 2 months from baseline
Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
2 months from baseline
Body Sensation Questionnaire
Time Frame: 8 months from baseline
Fear of bodily symptoms, score ranging from 0 to 72 . Higher scores indicate more fear of body sensations.
8 months from baseline
Patient Health Questionnaire-9
Time Frame: Baseline
Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
Baseline
Patient Health Questionnaire-9
Time Frame: 2 months from Baseline
Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
2 months from Baseline
Patient Health Questionnaire-9
Time Frame: 8 months from Baseline
Measure of depression, score ranging 0 to 27 with a higher score indicating higher level of depression.
8 months from Baseline
The Godin Leisure-time Exercise
Time Frame: 2 months from Baseline
Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
2 months from Baseline
The Godin Leisure-time Exercise
Time Frame: 8 months from Baseline
Level of physical activity. The participant rate numbers of time per week that they engage in physical activity. The numb ers are the categorized in to low, moderate, and high levels of physical activity.
8 months from Baseline
Tampas Scale for Kinesophobia-Heart version
Time Frame: 2 months from Baseline
Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
2 months from Baseline
Tampas Scale for Kinesophobia-Heart version
Time Frame: 8 months form Baseline
Fear of physical activity. The total score varies between 17 and 68, with higher values indicating more severe kinesiophobia.
8 months form Baseline
Client satisfaction Questionnaire
Time Frame: 2 months from Baseline
Treatment satisfaction, score ranging from 0 to 32, with a higher score indication more satisfaction with the treatment.
2 months from Baseline
Adverse events
Time Frame: 2 months from baseline
Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').
2 months from baseline
Adverse events
Time Frame: 8 months from baseline
Potential adverse reactions to the treatment. Participants will be asked to report and rate the short- and long term discomfort of the adverse event on a scale from 0 ('did not affect me at all') and 3 ('affected me very negatively').
8 months from baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 29, 2020

Primary Completion (Actual)

December 1, 2021

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

November 24, 2020

First Submitted That Met QC Criteria

November 24, 2020

First Posted (Actual)

December 2, 2020

Study Record Updates

Last Update Posted (Actual)

May 24, 2022

Last Update Submitted That Met QC Criteria

May 23, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Infarction

Clinical Trials on MI-CBT

3
Subscribe